Calidi Biotherapeutics Inc (CLDI)
2.025
-1.36
(-40.09%)
USD |
NYAM |
Nov 14, 16:00
2.05
+0.02
(+1.23%)
After-Hours: 20:00
Calidi Biotherapeutics Net Income (Quarterly): -5.767M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -5.767M |
| March 31, 2024 | -7.225M |
| December 31, 2023 | -8.229M |
| September 30, 2023 | -2.024M |
| June 30, 2023 | -12.50M |
| Date | Value |
|---|---|
| March 31, 2023 | -6.462M |
| December 31, 2022 | -7.756M |
| September 30, 2022 | -5.355M |
| December 31, 2021 | -3.489M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-12.50M
Minimum
Jun 2023
-2.024M
Maximum
Sep 2023
-6.534M
Average
-6.462M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| Lumos Pharma Inc | -7.551M |
| NovaBay Pharmaceuticals Inc | -1.585M |
| Palatin Technologies Inc | -8.250M |
| iBio Inc | -7.778M |
| Theriva Biologics Inc | -8.316M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.591M |
| EPS Diluted (Quarterly) | -14.00 |
| Enterprise Value | 31.40M |
| Earnings Yield | -973.7% |